Accelerated the deployment of Nanox ARC in the US market, Submitted a new 510k application to the FDA to expand…
JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the…
Media Release Oral presentation will detail results from the randomized TACTI-003 Phase IIb trial in first line head & neck…
DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform…
Priority Review Voucher would be issued upon approval of OPGx-LCA5RESEARCH TRIANGLE PARK, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Opus…
RESEARCH TRIANGLE PARK, N.C., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing…
Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and…
SCOTTSDALE, Ariz., Aug. 20, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care…
caption: Sabin Vaccine Institute Research & Development President Kelly Warfield WASHINGTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Virologist and vaccine…
CATALYST is a Phase 2 single-blind, placebo-controlled, proof-of-concept study in patients presenting to the emergency department More than 27,569 individuals…